HIV

Abdominal Fat Accumulation in HIV: Interview with Dr Grinspoon

Nelson Vergel from PowerUSA.org interviews Dr Steven Grinspoon from Harvard Medical School about what we know about HIV lipodystrophy associated fat accumulation. Dr Grinspoon covers potential causes and treatments. For more information please refer to the closing image at the end of the video. QUESTIONS FOR DR GRINSPOON’S INTERVIEW: 1. Please give our audience background …

Abdominal Fat Accumulation in HIV: Interview with Dr Grinspoon Read More »

Interview with Dr Gerald Pierone About HIV Lipodystrophy Options

Nelson Vergel, director of Program for Wellness Restoration, interviews Dr Pierone about his long experience treating patients with HIV facial lipoatrophy and his upcoming study for patients with HIV related abdominal fat accumulation. His website is www.FacialRejuvenationFL.com You can also ask him questions on TheBody.com. You can also find more info on PoWeR’s site www.FacialWasting.org …

Interview with Dr Gerald Pierone About HIV Lipodystrophy Options Read More »

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

This is a study required by the FDA to determine if Egrifta use in HIV+ people with diabetes can increase the risks of diabetic retinopathy. https://clinicaltrials.gov/ct2/show/NCT01591902 Diabetic retinopathy  is a complication of diabetes that affects the eyes. It’s caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye …

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Read More »

New treatments for HIV associated lipodystrophy beyond Egrifta

Question from a person living with HIV: May 2, 2012 I body build and work out, eat right, etc. The lipodystrophy I accumulated during my early use of Crixivan and others doesn’t really go away that much. It’s frustrating, depressing. I do also appear to have some features of “muscle belly” where there is a space between …

New treatments for HIV associated lipodystrophy beyond Egrifta Read More »

What to do if you think you have recently been exposed to HIV

This would definitely be the HIV medication combo that I would take if I was HIV negative and wanted to treat a potential HIV exposure (condom breakage, needle stick, etc). Prior studies were done using Truvada alone (two drugs combined in one pill), but adding raltegravir to Truvada makes a lot of sense. Raltegravir (brand …

What to do if you think you have recently been exposed to HIV Read More »

PoWeR asks for your support and end of year tax deductible donation

Program for Wellness Restoration (PoWeR,  https://powerusa.org/  ) is going through a tough financial time now that most industry educational grants have been eliminated.  We ask you to think about us when conmsidering organizations to make tax deductible donations before the end of the year. In 2011, PoWeR has been able to accomplish the following with …

PoWeR asks for your support and end of year tax deductible donation Read More »

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options

Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many …

The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »

Update on Medicare’s Decision to Help People with HIV-associated Facial Lipoatrophy

I sent this email to Medicare: Sent: Wednesday, March 31, 2010 10:53 AM To: Baldwin, JoAnna F. (CMS/OCSQ) Subject: From the feedback tool – 100331-000018 Regarding:Decision Memo for Dermal injections for the treatment of facial lipodystrophy syndrome (FLS) (CAG-00412N) I have the following questions: 1- Do patients have to remain depressed to get yearly touch …

Update on Medicare’s Decision to Help People with HIV-associated Facial Lipoatrophy Read More »